SCH-58261-loaded cross-linked multilamellar liposomes with maleimide functionalization on the surface of CAR T cells have been designed in models of ovarian cancer and chronic myelogenous leukemia to target the A2a adenosine receptor (A2aR) inhibitory pathway involved in T cell receptor signaling inhibition and IFNγ production through elevated intracellular cyclic AMP adenosine levels that are increased in the tumor microenvironment. Here, ADORA2A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.